Results 191 to 200 of about 514,735 (343)
We show that intratumoral release of an immunotherapy—CpG —can be tuned with molecular precision by complexing it to an elastin‐like polypeptide (ELP). Injecting ELP‐CpG and an excipient ELP into tumors drives thermally‐triggered phase separation into a micro‐scale “sponge” depot that releases CpG at rates depending on the ELP composition, which ...
Joshua J. Milligan+16 more
wiley +1 more source
Immunosuppressant management in palliative care: a systematic review. [PDF]
Birchler KM+4 more
europepmc +1 more source
Specific and Non-Specific Immunosuppression in Chickens [PDF]
P. Thaxton, Patricia S. Young
openalex +1 more source
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression [PDF]
Demetris, AJ+3 more
core
cmExoaCD11b induced the repolarization of immunosuppressive M2 macrophages into pro‐inflammatory M1 phenotype, thereby promoting the proliferation and activation of CD8+ T cells and reversing the immunosuppressive state of the tumor microenvironment.
Man Sun+14 more
wiley +1 more source
Immunosuppression in rabbits: skin and kidney allografts [PDF]
C. J. Green
openalex +1 more source
Weaning of immunosuppression in long-term recipients of living related renal transplants: A preliminary study [PDF]
Fung, JJ+5 more
core
B‐OMVs, nanoscale vesicles derived from BCG, are identified as effective and safe inducers of trained immunity that protect against sepsis. Through TLR2‐mediated metabolic and epigenetic reprogramming of hematopoietic stem cells, B‐OMVs enhance inflammatory response and phagocytic activity.
Yuan Gong+16 more
wiley +1 more source
Intra-Epithelial Carcinoma of the Vagina following Immunosuppression Treated with Topical 5-Fluorouracil [PDF]
Peter Bowen‐Simpkins, M.G.R. Hull
openalex +1 more source